Any current/future new fundraising through debt or equity?

There is no explicit mention of any current or planned new fundraising through debt or equity in the transcript. The company is focused on monetizing real estate assets, particularly through a structured joint development deal for its Thane land, rather than raising funds through equity or debt. Satish Varma mentions that monetization of real estate will play a large role in funding expansions such as the Saykha CAPEX. The management indicated no immediate plans or discussions about equity or debt fundraising; emphasis is on asset monetization and internal funding. They are also focused on com

Any current/future capex/capital investment/strategic investment?

The company is investing around Rs. 40 crores in a premix plant located in Kullu to expand its product basket, expected to be operational in 8 to 10 months. They plan further expansion through a larger Saykha plant once real estate monetization is sufficiently progressed. Real estate monetization, including the Thane land development deal, is intended to fund future CAPEX especially for the Saykha facility. The Saykha CAPEX has been delayed but is a key growth driver. Management is adopting a dynamic approach, utilizing existing capacities while preparing for Saykha's launch. No immediate invo

Future growth expectations in sales/revenue/volumes?

Human Vitamin D3 demand is expected to stabilize at levels higher than pre-pandemic, supported by increasing awareness of its immunity benefits. Animal feed Vitamin D3 volumes showed a 145% increase in Q3 FY22 vs. last year but faced price pressure, indicating volume growth may continue but with cyclical price volatility. German subsidiary started sales in Q3 FY22 with INR 6.1 crores revenue; further growth depends on feed market prices and customer approvals. US subsidiary is expanding human nutrition portfolio to balance animal feed dependence, aiming for 45%-50% human nutrition share in the

Future growth expectations in earnings/operating earnings/profits/EPS?

Fermenta Biotech aspires to reach Rs. 1,000 crore turnover in the next 5 to 6 years, indicating strong top-line growth ambitions. Animal feed volumes are expected to pick up, with prices having bottomed out, suggesting margin improvement potential. German subsidiary anticipated to become more profitable as animal feed prices recover; breakeven impacted by initial inventory revaluation and trial costs. US subsidiary focusing on increasing the human nutrition segment to balance portfolio and improve stability. Real estate monetization (sale of IT buildings, land) expected to fund CAPEX for new p

Current/ Expected Orderbook/ Pending Orders?

The transcript does not explicitly mention the current or expected order book or pending orders for Fermenta Biotech Limited. However, it is noted that the German subsidiary received required approvals in Q3 FY22 and clocked sales of INR 6.1 crores, with expectations to maintain or improve volumes as more customer approvals come. For the feed market, volumes are picking up with prices stable at $12 to $14 per unit as per Feed Info. Regarding real estate monetization, ongoing efforts to monetize land and buildings, which could provide funding for CAPEX. Overall, while specific order book number

Fermenta Biotech LtdQ3 FY22Pharmaceuticals & Biotechnology

Fermenta Biotech Ltd Q3 FY22 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹553P/E: 25.2Market Cap: ₹1.4K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

Human Vitamin D3 demand is expected to stabilize at levels higher than pre-pandemic, supported by increasing awareness of its immunity benefits.
Animal feed Vitamin D3 volumes showed a 145% increase in Q3 FY22 vs. last year but faced price pressure, indicating volume growth may continue but with cyclical price volatility.
German subsidiary started sales in Q3 FY22 with INR 6.1 crores revenue; further growth depends on feed market prices and customer approvals.
US subsidiary is expanding human nutrition portfolio to balance animal feed dependence, aiming for 45%-50% human nutrition share in the US market within three years.
Premix plant in Kullu (Rs. 40 crores investment) underway to support basket expansion ahead of Saykha plant commissioning.
Real estate monetization expected to fund Saykha CAPEX, facilitating manufacturing growth of nutraceutical products.
Overall, growth drivers include new capacities, geographic expansion, and product diversification in human nutrition.

Margin guidance

Category 3

Fermenta Biotech aspires to reach Rs. 1,000 crore turnover in the next 5 to 6 years, indicating strong top-line growth ambitions.
Animal feed volumes are expected to pick up, with prices having bottomed out, suggesting margin improvement potential.
German subsidiary anticipated to become more profitable as animal feed prices recover; breakeven impacted by initial inventory revaluation and trial costs.
US subsidiary focusing on increasing the human nutrition segment to balance portfolio and improve stability.
Real estate monetization (sale of IT buildings, land) expected to fund CAPEX for new plant expansions, aiding growth.
Premix plant expected operational in 8-10 months, diversifying product offerings and enhancing margins.
Introduction of new products like fish oil cholesterol and Vegan D3 aimed at reducing volatility and increasing revenue.
Current low EBITDA margins due to pricing cycles and one-time costs; margin normalization expected as demand and prices improve.

See what Fermenta Biotech Ltd management said on margin guidance — free account, 30 seconds.

Fundraise plans

There is no explicit mention of any current or planned new fundraising through debt or equity in the transcript.
The company is focused on monetizing real estate assets, particularly through a structured joint development deal for its Thane land, rather than raising funds through equity or debt.
Satish Varma mentions that monetization of real estate will play a large role in funding expansions such as the Saykha CAPEX.
The management indicated no immediate plans or discussions about equity or debt fundraising; emphasis is on asset monetization and internal funding.
They are also focused on completing ongoing merger processes before any major structural financial moves like a new listing on NSE.

Order book

The transcript does not explicitly mention the current or expected order book or pending orders for Fermenta Biotech Limited.
However, it is noted that the German subsidiary received required approvals in Q3 FY22 and clocked sales of INR 6.1 crores, with expectations to maintain or improve volumes as more customer approvals come.
For the feed market, volumes are picking up with prices stable at $12 to $14 per unit as per Feed Info.
Regarding real estate monetization, ongoing efforts to monetize land and buildings, which could provide funding for CAPEX.
Overall, while specific order book numbers are not stated, the company shows optimism about increasing volumes and sales in both animal feed and human nutrition segments as approvals progress and market conditions improve.

See what Fermenta Biotech Ltd management said on order book — free account, 30 seconds.

Capex plans

Yes

The company is investing around Rs. 40 crores in a premix plant located in Kullu to expand its product basket, expected to be operational in 8 to 10 months.
They plan further expansion through a larger Saykha plant once real estate monetization is sufficiently progressed.
Real estate monetization, including the Thane land development deal, is intended to fund future CAPEX especially for the Saykha facility.
The Saykha CAPEX has been delayed but is a key growth driver.
Management is adopting a dynamic approach, utilizing existing capacities while preparing for Saykha's launch.
No immediate involvement in construction or development—the company contributes land and receives developed carpet area in return.
Other strategic moves include exploring value addition closer to European or American markets.

Track Fermenta Biotech Ltd — get its next earnings analysis in your feed

How does Fermenta Biotech Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

ThisFermenta Biotech Ltd

Rev 3Mar 3

See where Fermenta Biotech Ltd sits in Pharmaceuticals & BiotechnologySee which companies these are, and every other name in the sector.Open rankings

How does Fermenta Biotech Ltd rank in Pharmaceuticals & Biotechnology?

Compare Fermenta Biotech Ltd against every Pharmaceuticals & Biotechnology company (Q3 FY22) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

What Fermenta Biotech Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

Natural Capsules Ltd (Q1 FY27)
Revenue from Operations for Q1FY27: ₹48.71 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q1 FY27 investor presentation — and how it ra
Aptus Pharma Ltd (Q4 FY26)
The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…
Aptus Pharma Ltd (Q1 FY27)
Revenue from Operations for H2 FY26: ₹32.20 crore, up 117.5% YoY from ₹14.80 crore in H2 FY25 (Page 23) . Key concall takeaways from Aptus Pharma Ltd's Q1 FY27…
RPG Life Sciences Ltd (Q2 FY25)
Q2 FY25: ₹172.2 Crores . Key concall takeaways from RPG Life Sciences Ltd's Q2 FY25 earnings call — and how it ranks against sector peers.

Compare:vs Sun Pharma.Inds.vs Divis Laboratories Ltd vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Fermenta Biotech Ltd Q3 FY22 Earnings Call Analysis

Revenue guidance

Fundraise plans

Capex plans

How does Fermenta Biotech Ltd rank in Pharmaceuticals & Biotechnology?

Continue your research

What Fermenta Biotech Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season